
ãã³ãããã¯æ¡çŽã广ãå®å šæ§ã®æ€èšŒãããç¥çè²¡ç£æš©ã®æŸæ£ã§ãããŠãã!?ã
2023幎11æ15æ¥ããè¶ å æŽŸWCHè°å¡é£çïŒä»®ç§°ïŒèšç«ç·äŒããåè°é¢è°å¡äŒé€šã§éå¬ãããŸãããåœäŒè°å¡ãå æŽŸãè¶ ããŠãWHOã®ãã³ãããã¯æ¡çŽãIHRæ¹æ£ã®å±éºæ§ã«ã€ããŠå£°ããããããšããé£çã§ããè°å¡ããå€åçãšååŽçã«è³ªåããå 容ãšãã¹ããŒã¯ãã«ããŒã®é¢é£èšäºãæãèµ·ãããèŠããŠããããšããŸãšããŠã¿ãŸããã
广ãå®å šæ§ãæ€èšŒããªããŸãŸäº€æžãé²ãå±éºæ§
ååã®ç¶ãã§ãã
ãã³ãããã¯æ¡çŽãIHRæ¹æ£ã¯ãã©ããåæã«æ±ºããããŠããŸãã®ã ããç¥ã£ãŠãã©ãã«ããªããªãïœ¥ïœ¥ïœ¥ãšæã人ããããããããŸãããããã©ããèªåã§èª¿ã¹ãŠç¥ã£ãŠãããªããã°ã決ãŸã£ãåŸã«ããã³ãããã¯æ¡çŽã§æ±ºãŸã£ãŠããã®ã§ããšèšãããããåŸããªããã°ãªããªããšæãããã§ããŸããããããŸãããå®ã¯ãåªå矩åã®ãããªãã®ã§ãå¿ ãããåŸãå¿ èŠããªãããšããããããããªãã®ã§ãã
ä»ãäœãèµ·ããŠãããç¥ãããšããããšããåœãå¥åº·ãå®ãããšã«ã€ãªãããšæããŸãã
11æ15æ¥ã®èšç«ç·äŒã§ã¯ãæ¥éåžè°äŒè°å¡ã®æ± ç°ãšããæ°ããååŽçã«åããŠãäžèšã®è³ªåããããŸããã
ã»IHRïŒåœéä¿éºèŠåïŒæ¹å®ã«ã€ããŠãåœäŒå¯©è°ã¯ãããã®ãïŒããããšãéŠçžã倧è£ã®äžä»»ãšããããšã§æçµçã«æ±ºãŸã£ãŠããã®ãïŒ
ã»ä»åã®ã¯ã¯ãã³æ¥çš®ã®æ¯éã«é¢ããçµ±æ¬ãšããã®ããåœæ°çç·æãšããŠã¯è¡ãããŠããªããå ã ã¯ã¯ãã³æ¥çš®ãWHOãäž»å°ã§æ¥æ¬ãå«ããŠäžçäžãåããŠãã®ã§ããã®ã¯ã¯ãã³æ¥çš®ãåœæ°ã«ã©ããã圱é¿ãäžããŠããã®ããšããããšã®çµ±æ¬ããããªãããæ¬¡ã®æ®µéã«é²ãã§ãããšããã®ãç©äºã®é åºã§ããã¯ãããã®ç¹ã«é¢ããŠã¯ãã©ã®ãããªè©äŸ¡ãããŠãããïŒ
ã»å°æ¹è°å¡ã¯ãæ»äº¡ã ãã§ãªãä»ããªãèŠãããæ¥çš®åŸããã«å ·åãæªããªã£ããããªãªã¿ãªããªãçç¶ã ãšãã人ããã®çžè«ã倿°åããŠãããã¯ã¯ãã³åç§äŒã®ã¡ã³ããŒã«å ãã¡ã€ã¶ãŒç€Ÿã»èšåºéçºçµ±æ¬éšé·ã®åå ææ° ã就任ããŠããŠãè°äºé²ãèŠããšåžžã«äŒè°ããªãŒãããŠãããæ¥æ¬äžã§ãã€ãŠãªãã»ã©ã®è¢«å®³ãåºãŠããã«ãé¢ããããå ãã¡ã€ã¶ãŒçµ±æ¬éšé·ã®ãªãŒãã«ãã£ãŠæ¥çš®æšé²ã®æ¹åã«åŒãããããŠããã®ã¯ãå©ççžåã§ã¯ãªãã®ãïŒ
å ãã¡ã€ã¶ãŒã®åå æ°ã«ã€ããŠã¯ãäžèšã®èšäºã§åãäžããŸããã
åçåŽåç
ã»IHRã®æ¹æ£å 容ããææçæ³ãªã©ãåœå æ³ã®æ¹æ£ãå¿ èŠã§ããã°åœç¶å¯©è°ããããIHRã®æ¹æ£ãæ¢ã«åœå æ³ã§æ ä¿ãããŠããå 容ã§ãã㰠審è°ã¯ããªãã
ã»ã¯ã¯ãã³é¢ä¿ã¯ãçŽæ¥ã®æ åœãä»ååå ããŠããªãã®ã§è©³çްã¯çããããªããæå¹æ§ãå®å šæ§ã¯ç§åŠçãªç¥èŠãæ å ±ãåéããŠã審è°äŒã®æ¹ã§è©äŸ¡ããŠããã
1ã€ãã®çåŒã¯ãæåŸã®æ¹ãããèãåããŸããããåœå æ³ã§æ ä¿ãããŠããå Žåã¯åœäŒã§ã¯å¯©è°ããªããšããããšã ãšæããŸãã
ã¯ã¯ãã³ã«é¢ããŠã¯ãã¡ãããšããåçã«ã¯ãªã£ãŠããªãã£ãã®ã§ãååã®èšäºã§åãäžããããã¢ããªã«æ¥æ¬åè°äŒãã®èšäºãããã®ãŒã£ãŠã¿ãŸããããã¢ããªã«æ¥æ¬åè°äŒãã®å ±å代衚ã¯ããã³ãããã¯æ¡çŽã®äº€æžã«ã¹ããŒã¯ãã«ããŒãšããŠåå ã§ãããJapan CSO Network for Global Healthãã®ä»£è¡šã§ããããŸãã
åœéä¿å¥ã«åãçµãNGOã»åžæ°ç€ŸäŒã®ãããã¯ãŒã¯ã§ãããGII/IDIæè«äŒNGOé£çµ¡äŒãïŒä»£è¡šïŒçš²å Žé çŽã»ã¢ããªã«æ¥æ¬åè°äŒå ±å代衚ïŒã¯ããã³ãããã¯æ¡çŽäº€æžã®ã¹ããŒã¯ãã«ããŒã®äžã€ã§ãããã¢ããã¯ã¹Eå£äœãã«ããããŒããããå亀æžã«ã€ããŠçŽæ¥ãåé¡æèµ·ãããããšãå¯èœãšãªããŸããã
ãã³ãããã¯æ¡çŽã®äº€æžãå§ãŸãåãäžèšã®èšäºã§ã¯ãéäžåœãžã®ã¯ã¯ãã³ã®äŸçµŠã倧ããªèª²é¡ãšãªã£ãŠããããšãšãã¯ã¯ãã³ã«é¢ããæ å ±å ¬éãšéææ§ã®èª²é¡ã«ã€ããŠæžãããŠããŸãã
2020幎11æ29æ¥
åžæ°ç€ŸäŒãæèµ·ããŠããã®ã¯ããŸãæ å ±å ¬éã®äžååãã§ããäžèšïŒã¯ã¯ãã³ã®ãææãã¯äžéçºè¡šã®æ®µéã§ãããé瀺ãããæ å ±ã¯ããããäžååãªãã®ã§ããã广ãã«ã€ããŠããå¯Ÿè±¡è æ°ãå°ãªããäººçš®ãæ§å¥ãæåŸãçæŽ»ç¶æ³ãªã©ç°ãªã£ãæ¡ä»¶ã§ãå®éã«ã©ã®çšåºŠå¹æãçºçŸããã®ãããŸãããªã¹ã¯ãã©ã®ããã«å€åããã®ãå šãå®ãã§ã¯ãããŸããã
ïŒäžç¥ïŒ
å»è¬åã®éææ§ãæ±ãããã©ã³ã¹ã®NGOãOT-MEDã代衚ã®ããŒãªãŒã³ã»ãã³ãã€ããïŒPauline LondeixïŒã¯ãã€ã¿ãŒéä¿¡ã«ãåºãããæ å ±ã¯æ¥µããŠäžååã§ãå»è¬åã¡ãŒã«ãŒãç«¶äºã«åã¡æãããã«éœåã®è¯ãæ å ±ãåºããŠããã ãã«ãããªããæ²»éšã®æ¹æ³ãšçµæãå šãŠå ¬éãããã¹ããªã®ã«ãéè¡ããŠããããšè¿°ã¹ãŠããŸãïŒæ³šïŒïŒã
ããŒã¿ã®éææ§ã«ã€ããŠã¯ãç±³åœã®äººæš©NGOãã¥ãŒãã³ã»ã©ã€ãã»ãŠã©ããããæè¿çºè¡šããå ±åæžãã¯ã¯ãã³ãçºèŠããè ã¯ã ãã§ããããšãã·ã§ã¢ããªããã°ãªããªãïŒCOVID-19ã¯ã¯ãã³ã®äººæš©ãšéææ§ã®åŒ·åïŒãã«ãããŠã詳现ã«è¿°ã¹ãŠããŸãã
ïŒæ³šïŒïŒReuters, âBritain and other nations press on with AstraZeneca vaccine amid trial questionsâ, November 27, 2020
2020幎11æé ã¯ãéäžåœã®ç®ç·ã§ãã®ãããªæèŠãã§ãŠããããšãããããŸãã
ãšããããæè¿ã®èšäºãèŠããšãéäžåœãäžå¿ãšããå£äœã¯ãšã«ãããå»è¬åãžã®å ¬æ£ãªã¢ã¯ã»ã¹ããæ±ããŠããå°è±¡ã§ããäžæ¹ãå é²åœã®éçºç³»è£œè¬æ¥çã¯ãç¥çè²¡ç£æš©ã®æŸæ£ããæ±ããããããšã«åçºãã亀æžãé£èªããŠããããã«èªã¿åããŸãã
ããã©ããã®æµãã®äžã§ãã¯ã¯ãã³ã®å®å šæ§ã«é¢ããæ€èšŒã«ã€ããŠã¯èŠããŠããŸããããªãã¯ã¯ãã³ãå®å šãªãã®ãšããåæã§ã話ãåããé²ããããŠããã®ã§ããããããšãŠãäžèªç¶ã«æããŸãããªãå®éã«æ¥çš®ãã人ãã¡ã®ããŒã¿ã§ãæ€èšŒãããªãã®ã§ããããã
ããã¯ã¯ãã³ãæ¬åœã«ãããã®ãªããéäžåœã«ãå ¬æ£ã«åé ãããããã«è©±ãåãå¿ èŠããããšæããŸãããããã ãå¥åº·è¢«å®³ãã§ãŠãããã®ããéäžåœã®äººãã¡ã¯æ¬åœã«æ±ããŠããã®ã§ãããããå¥åº·è¢«å®³ã®æ å ±ã¯ãéäžåœã®äººãã¡ã«å±ããŠããã®ã§ããããã
ãã³ãããã¯æ¡çŽããããŸã§ã®æµã
ãã¢ããªã«æ¥æ¬åè°äŒãã®èšäºããã¯ããããŸã§ã®æµããç¥ãããšãã§ããŸãã以äžãèšäºãããã€ã³ããæžãåºããŸããã
é·ããªã£ãŠããŸããŸããããç§ãåããŠnoteã«æžããèšäºã«ãã€ãªããæãèµ·ããã«ãªããŸããã
2021幎12æ28æ¥
ããã³ãããã¯æ¡çŽãã«ã€ããŠã¯ã2020幎ç§é ãããæ¬§å·è«žåœãäžå¿ã«ããããå¶å®ãã¹ããšããåãã匷ãŸã£ããšæžãããŠããŸãã
ãã³ãããã¯æ¡çŽïŒã ãã®å©çã«ãªãã®ãïŒïŒç¬¬ïŒäžçãããã¯ãŒã¯ïŒ
äžèšã¯ãéçºéäžåœã®éçºãšè²¿æã»æè³ã»æŽå©ã®èª²é¡ã«åãçµãã§ããã第ïŒäžçãããã¯ãŒã¯ãïŒThird World NetworkïŒåšã¯ã¢ã©ã«ã³ããŒã«ïŒã 2021 幎 10 æã«çºè¡šãããäžçä¿å¥æ©é¢ïŒWHOïŒã軞ã«é²ãããã³ãããã¯æ¡çŽãã«é¢ãã亀æžã«ã€ããŠã®åæèšäºã®æ¥æ¬èªèš³ãšã®ããšã
以äžãäžéšåŒçšã§ãã
欧å·å§å¡äŒã®ãã³ãããã¯æ¡çŽã«é¢ããææ¡ã¯ãææåã®ããæ³åŸãéžæçã«çšããŠæ¬§å·é£åã®ä¿å¥å®å šä¿éäžã®å©çã確ä¿ãã€ã€ãå ¬è¡è¡çã«é¢ãã調æŽãšååã®èŠä»¶ã¯ææåã®ãªãæ³ã®ã¡ã«ããºã ã«å§ããããšãç®æããŠãããšããææãè£ä»ãããã®ã§ãããã€ãŸããæ¢åã®åœéä¿å¥èŠåã®äžã§ååã®æ³ç矩åã匷åããããæ³çææåããã£ãŠã¿ã€ã ãªãŒãã€å ¬å¹³ãªå»è¬åãžã®ã¢ã¯ã»ã¹ã匷åããããããšããæ¿æ²»çæ©éã¯ã欧å·é£åå ã«ã¯ã»ãšãã©ååšããªãã®ã§ããã
2022幎7æ31æ¥
ã»ããã³ãããã¯æ¡çŽãã®äº€æžã¯ã2020å¹Žã«æ¬§å·é£åã®ã·ã£ã«ã«ã»ãã·ã§ã«æ¬§å·çäºäŒè°é·ãæå±ããããšã§å§ãŸã£ãã
ã»ããã³ãããã¯æ¡çŽãã¯ãWHOãCOVID-19ãžã®å¯Ÿå¿ãæ€èšŒããä»åŸã®ãã³ãããã¯å¯Ÿå¿ã®åšãæ¹ãèŠçŽãããã«èšçœ®ããããã³ãããã¯å¯Ÿçã»å¯Ÿå¿ç¬ç«ããã«ãïŒIPPPRïŒã®å ±åæžã§ãæ¯æãããã
ããã³ãããã¯å¯Ÿçã»å¯Ÿå¿ç¬ç«ããã«ãã®å ±åæžããã
ç¬ç«ããã«ã匷調ãããæ§ç¯ãã¹ãåãã«ã€ããŠ
ã» ã¯ã¯ãã³ã¯åäŸã®ãªãã¹ããŒãã§éçºããããæ°åã³ãããŠã€ã«ã¹ãé壿æãåŒãèµ·ãããããšã確èªãããŠããæ°æ¥ä»¥å ã«ã¯ã¯ãã³éçºãé²ããããèšé²çãªéãã§å€ãã®ã¯ã¯ãã³ãæ¿èªããããä»ãã COVID-19 ã®ææãå šäžççã«æå¶ããããã«ãã¯ã¯ãã³ãããå ¬å¹³ã§æŠç¥çã«é åžãããªããã°ãªããªãã
ã» ãªãŒãã³ããŒã¿ãšãªãŒãã³ãµã€ãšã³ã¹ã®ã³ã©ãã¬ãŒã·ã§ã³ã¯ããã³ãããã¯ã®èŠæãšå¯Ÿå¿ã«ãããŠäžå¿çãªåœ¹å²ãæããããäŸãã°ãæ°åã³ãããŠã€ã«ã¹ã®ã²ãã é åããªãŒãã³ãã©ãããã©ãŒã ã§å ±æãããããšã«ãããå²äžæãæ©ãããŠã€ã«ã¹ææã®èšºææ€æ»ãéçºãããããšãšãªã£ãã
ã»ãæ¿åºé亀æžäž»äœãïŒIntergovernmental Negotiating Body: INBïŒã亀æžããã»ã¹ã管çãã圢ã§ãæ€èšãé²ãã§ããããã®ãã³ãããã¯æ¡çŽã¯ãçŸç¶ã§ã¯ãæ¡çŽãïŒConventionïŒãšãªãããåæïŒAgreementïŒãšãªããããã®ä»ã®åœéçåæ±ºãïŒOther International InstrumentïŒãšãªããæ±ºããããŠããªãã
ã»INBã¯WHOã®ãã¹ãŠã®å çåœã«éãããŠãããããã®é²è¡ããã»ã¹ãæ€èšããŠããã®ã¯ãWHOã®å°ååºåæ¯ã«éžåºããããã©ãžã«ïŒç±³å·ïŒããšãžããïŒæ±å°äžæµ·ïŒãæ¥æ¬ïŒè¥¿å€ªå¹³æŽïŒããªã©ã³ãïŒæ¬§å·ïŒãåã¢ïŒã¢ããªã«ïŒãã¿ã€ïŒåæ±ã¢ãžã¢ïŒã®ïŒãåœã§æ§æãããããã¥ãŒããŒãïŒBureauïŒã
ã»ãã¥ãŒããŒã¯åã¢ã®ãã¬ã·ã£ã¹ã»ããã©ãœæ°ïŒPrecious MatsosoïŒãšãªã©ã³ãã®ããŒã©ã³ãã»ã°ãªãŒã¹æ°ïŒRoland GrieceïŒãè°é·ãä»ã®ïŒãåœã®ä»£è¡šãå¯è°é·ãšãªã£ãŠé²è¡ã
å€åçã®çåŒã«ãããšãæ¥æ¬ããã¯å¯è°é·ãšããŠæ¬æž èé 倧䜿 (åšãžã¥ããŒãæ¥æ¬æ¿åºä»£è¡šéš)ãéžåºããããšã®ããšãæ¬æž èé æ°éžåºã«ã€ããŠã¯ãäžèšã«ãæžãããŠããŸãã
åè¿°ã®ãç¬ç«ããã«ã匷調ãããæ§ç¯ãã¹ãåãã«ã€ããŠãã«ã¯ããæ°åã³ãããŠã€ã«ã¹ãé壿æãåŒãèµ·ãããããšã確èªãããŠããæ°æ¥ä»¥å ã«ã¯ã¯ãã³éçºãé²ããããèšé²çãªéãã§å€ãã®ã¯ã¯ãã³ãæ¿èªãããããšæžãããŠããŸããããå®å šæ§ã«ã€ããŠã¯è§ŠããããŠããŸããã
ãŸãããæ°æ¥ä»¥å ã«éçºãé²ããããããšããã®ã¯ãæ©ããããšæãã®ã§ããã
ç¹äŸæ¿èªã®å¯©æ»å ±åæžãèŠããšãäžèšãé»å¡ãã«ãªã£ãŠããããšãnote1æ¬ç®ã®èšäºã§åãäžããŸããïŒäžèšåç §ïŒã

æŠæŒ¢åžã§çºçããèºçãæ°åã³ãããŠã€ã«ã¹ã«ãããã®ã ãšWHOãçºè¡šããã®ã2020幎1æ12æ¥ãšæžãããŠããã®ã§ããæ°æ¥ä»¥å ããšããããšã¯ãé»å¡ãéšåã¯1æãšããããšã«ãªãã§ããããæåã®å¹ ããã1æã ãšæããŸããããªãé ãå¿ èŠããã£ãã®ã§ããããã
ãããŠããã³ãããã¯æ¡çŽã§ã¯ããããããæ©ã察å¿ããããšãç®æããŠããããã§ãã
2022幎11æ23æ¥
ã»ããã³ãããã¯æ¡çŽãã¯ãIHRãå°éãã€ã€ããã³ãããã¯ãšåœéä¿å¥ã«é¢ãããããå¹ åºãé åã«ã€ããŠãååœã®äž»æš©ãå°éãã€ã€ãåœéçãªåæã圢æããããšãã詊ã¿ã§ããã
ã»ãããŸã§ãã³ãããã¯ã«é¢ããå»è¬åãžã®å ¬æ£ãªã¢ã¯ã»ã¹ãæ±ããŠããåžæ°ç€ŸäŒã¯ãåºæ¬çã«ãã®èæ¡ã«æè¿ã®æã衚æã
2023幎2æ23æ¥
ã»2023幎2æ1æ¥ã«ããŒãã»ãã©ããããéä»ãããŒãã»ãã©ãããã¯ãæšå¹Ž11æ16æ¥ã«å çåœã«éä»ããã第3åINBã§å çåœçã®è°è«ã«äŸããããæŠå¿µçåºç€èæ¡ãïŒConceptual Zero DraftïŒã«ã€ããŠãå çåœããã®æèŠãå ¥ããŠãŽã¡ãŒãžã§ã³ã»ã¢ãããããã®ã
2023幎5æ7æ¥
ã»ãåœéä¿å¥èŠåãã®æ¹å®äº€æžã«ã€ããŠã¯ããåœéä¿å¥èŠåãæ¹å®äœæ¥éšäŒïŒWGIHRïŒã亀æžã®èå°ãšãªã£ãŠããããã®äºã€ã®äº€æžã«ã¯éè€ããå 容ãå€ãããšãããæŽçãå¿ èŠãšã®æèŠãããã®ãŸãŸã§ã¯æ¥å¹Ž5æã®äžçä¿å¥ç·äŒãšããã¿ã€ã ãªãããã«éã«åããªããšã®æèŠã匷ãåºãããŠããã
ã»ãåœéä¿å¥èŠåãæ¹èšäœæ¥éšäŒã¯äºåã«ãåœéä¿å¥èŠåã®æ¹å®ã«åããŠååœãæåºããææ¡ããŸãšãããæ¡æããšã®ãŸãšãããå ¬éã
ã»ç±³åœã®ææ¡ã¯ãå çåœã®åãçµã¿ããåœéä¿å¥èŠåã«åºã¥ããŠååœããæåºãããæ
å ±çãå®éã«åœéä¿å¥èŠåã«åŸã£ããã®ã§ããããã¢ãã¿ãŒããããåœéä¿å¥èŠåã«é¢ããå çåœã®èœå匷åã«ã€ããŠå©èšãããããããšãç®çãšãããæ³ä»€éµå®å§å¡äŒããæ°ãã«èšçœ®ãããšãããã®ã
ã¢ããªã«ã»ã°ã«ãŒãã®ææ¡ã¯ãåæ§ã«å çåœã®åãçµã¿ãåœéä¿å¥èŠåã«åŸã£ãŠãããã©ãããã¢ãã¿ãŒãã€ã€ãå çåœãåœéä¿å¥èŠåã«åŸã£ãŠè¡åã§ãããããªæè¡ååãè³éæŽå©ãªã©ã®æäŸã«ã€ããŠå©èšããããä¿é²ãããããããšãç®çãšããã宿œå§å¡äŒããæ°ãã«èšçœ®ãããšãããã®ã
ã»ã¢ããªã«ã»ã°ã«ãŒãã¯ããã«å ããŠããä¿å¥ç·æ¥äºæ ãžã®åããšå¯Ÿå¿ã®å ¬å¹³æ§ã®ããã®è³éã¡ã«ããºã ããWHOã«èšçœ®ããããšãææ¡ã
â»ãã®èšäºã«ã€ããŠã¯ãåœéä¿å¥æ¿çã«é¢ããç¬ç«èª¿æ»ã»å ±éæ©é¢ã§ãããGeneva Health Filesãã®è€æ°ã®èšäºãåèã«ãããšã®ããšã
2023幎6æ4æ¥
ãã®ãèµ·èã°ã«ãŒããã¯ãæšå¹Ž12æã«éå¬ããã第3åINBã§ããã®æ§æãããæ¹ãå®ããããããåºæ¬ãWHOå çåœãšãªãã¶ãŒããŒïŒHoly SeeïŒïŒãŽã¡ãã£ã«ã³ïŒãšãã¬ã¹ããïŒããã³å°åå ±åäœçãã¡ã³ããŒãšãªããè©³çŽ°ãªæèšèª¿æŽãªã©ã®äº€æžãè¡ãããäŒè°äœãšãªã£ãŠããã
ã»ãã³ãããã¯æ¡çŽã®æ°ããªèæ¡ããã¹ãïŒDraft Bureauâs Text of the WHO CA+ïŒãå çåœçã«å ±æãããã
ã»ãŒãã»ãã©ããã38ç« ã ã£ãã®ã«å¯ŸããŠããã¡ãã¯41ç« ç«ãŠãšãªã£ãŠããã
ãã®èšäºãèªãã§ãªãã¶ãŒããŒã«ãHoly SeeïŒïŒãŽã¡ãã£ã«ã³ïŒãå ¥ã£ãŠããããšãæ°ã«ãªããããã«èª¿ã¹ãŠã¿ããšãããå¥ã®èšäºã«ã2021幎2æã«ãŽã¡ãã«ã³ïŒHoly SeeïŒãžã¥ããŒã代衚éšã®ã€ãŽã¡ã³ã»ãŠã«ã³ãŽã£ãå€§åžæã声æãçºè¡šãããšæžãããŠããŸããã
声æã®äžã§ããã¯ã¯ãã³ããã¹ãŠã®äººã«ãšã£ãŠã®æ®éçãªãã®ã§ãªããç¹å®ã®åœã®ææç©ã«ãªããšããããæ²ããããšã ããšãããã©ã³ã·ã¹ã³æçã®çºèšããã£ããšæžãããŠããŸãã
2021幎1æã«ã¯ãæçèªèº«ãæ¥çš®ããŠãæ¥çš®ãåŒã³ãããããšãå ±ããããŸããã
ããã«ã2021幎2æã«ããŒãæçåºã¯ãè·å¡ãæ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã®æ¥çš®ãæåŠããå Žåãè§£éãããåŸããšããæ³ä»€ãå ¬åžãæ¹å€ãåããŠãããã«ã¯ã¯ãã³æ¥çš®ãæãŸãªãè·å¡ã«ã¯ã代æ¿ã®éžæè¢ããæäŸãããšã®å£°æãçºè¡šããŸããã
ãã®ãããªèããæã€ããã«ã³ã¯ã亀æžã«ã©ã®ãããªåœ±é¿ãäžããŠããã®ã§ããããã
2023幎7æ1æ¥
ã»è°è«ã®è çãèŠãããäžã§ã亀æžèªäœã®éææ§ãäœäžãã亀æžã®äžã§æ¿åºä»¥å€ã®äž»äœãåå ã§ããªãããšãå€ããªã£ãŠããããšã«ã€ããŠãåžæ°ç€ŸäŒã¯èŠéã鳎ãããŠããã
ã»æ°ããªãã©ããã«å¯ŸããŠã¯ããã³ãããã¯è¡åãããã¯ãŒã¯ïŒPANïŒããã°ããŒãã«ãã¡ã³ã掻åè ãããã¯ãŒã¯ïŒGFANïŒãªã©å¹Ÿã€ãã®å£äœããå ¬åŒã«æèŠã衚æããŠããã
2023幎10æ28æ¥
ã»åœé補è¬å£äœåäŒïŒIFPMAïŒã¯ãããã¹ãéä»ã®ç¿æ¥ã«æ¥µããŠç Žå£çãªå£°æãåºãããIFPMAã¯ãã®å¶åºŠã«ãã£ãŠãç ç©¶è ãç åäœæ å ±ã«ã¢ã¯ã»ã¹ããã®ãé ãããããã¯ã¯ãã³ãæ²»çè¬ã®éçºã®é ãã«ã€ãªãããšäž»åŒµããŠããã
â»åœé補è¬å£äœåäŒïŒIFPMAïŒã¯ãAnnex Cã®ã¹ããŒã¯ãã«ããŒïŒWHOãšå ¬åŒé¢ä¿ã«ããéåœå®¶é¢ä¿è ïŒãšããŠãªã¹ãã«å ¥ã£ãŠããŸãã

ã¹ããŒã¯ãã«ããŒã«ã€ããŠã¯ãååã®èšäºã§åãäžããŸããã
ã亀æžããã¹ããã®å 容ã ãšããã³ãããã¯çºçæã«ç§åŠè ãç ç©¶ãè¿ éã«å®æœããããã«å¿ èŠãªç åäœãžã®ã¢ã¯ã»ã¹ãé ãããå¯èœæ§ãããããšããæ°ããªã¯ã¯ãã³ãæ²»çè¬ã®éçºã«äžå¯æ¬ ã ã£ã補è¬äŒç€Ÿãžã®ã€ã³ã»ã³ãã£ããæããã«æ¬ åŠãããªã©ãšæžãããŠããŸãããããŠããããæ¡æãããã°ã2021幎ã«G7ãå®ããã¯ã¯ãã³ã®ã100æ¥éããã·ã§ã³ãã¯å€±æããã ãããšã
ãããŠIFPMAäºåå±é·ã®ããŒãã¹ã»ã¯ãšãæ°ã¯ãããããªãããæ¡çŽãªãããªãæ¹ãããããšãŸã§èšã£ãŠããŸãã

第 11 æ¡ã«ãç¥çè²¡ç£æš©ã®å é€ãæªçœ®ã«ã€ããŠæžãããŠããããšããåé¡ãšãªã£ãŠããããã§ãã
ç¥çè²¡ç£æš©ã®æéä»ãæŸæ£ã«ã€ããŠãæ¥æ¬ã®ç ç©¶è ã補è¬äŒç€Ÿã®äººãã¡ã¯ãã©ã®ããã«èããŠããã®ã§ããããã
ãã®ã»ãããã¢ããªã«æ¥æ¬åè°äŒãã®èšäºã§ã¯ã人暩ã«é¢ããéšåãããªãåé€ãããŠããããšã«ãè§ŠããããŠããŸããã

ãããããããããããããâãâãâ
ã亀æžããã¹ãã

ã亀æžããã¹ããã«ã¯ãéå»ã®ããŒãã»ãã©ããããããã¥ãŒããŒåæ¡ããšæ¯èŒããŠã人暩ããå ¬æ£ãªã¢ã¯ã»ã¹ã®ããã®æªçœ®ãªã©ã®é¢ã§æ·±å»ãªåŸéãèŠãããã
ãšããæãã§äº€æžã¯ããŸããã£ãŠããªãããã§ããã倧ã©ãã§ãè¿ãããããããããŸãããããã¯ãIHRæ¹æ£ã®æ¹ãéèŠã«ãªã£ãŠãããããããŸããã
ç§ãã¡ã¯äº€æžã«çŽæ¥é¢ããããšã¯ã§ããŸããããåœæ°ãé¢å¿ãæã¡ãç¥ãããšåªåããããšã«ã¯ã倧ããªæå³ããããšæããŸãã
åé ã®æ± ç°æ°ã«ãã質çéšåã¯YouTubeã ãšãBAN(åé€)察çã§ãã¥ãŒãã«ãªã£ãŠãããããã®ã§ããã³ãã³åç»ã§å
¬éãããŠãããã®ãããããã§ãïŒ56åé ïŒã
èšç«ç·äŒãå
šç·š